AUTHORS
Philipp Berning, MD, Jacopo Calabrese De Feo, MD2, Rita Tavarozzi Jr, MD,PhD3, Giulio Cassanello4, Suheil Albert Atallah-Yunes, MD5, Alexander P. Boardman, MD6, Zachary Epstein-Peterson, MD7, Lorenzo Falchi, MD8, Paul Hamlin, MD9, Steven Horwitz, M.D.10, Anita Kumar, MD11, Jennifer Kimberly Lue, M.D.12, Efrat Luttwak, MD13, Alison Moskowitz, MD14, Colette Owens, MD15, Maria Lia Palomba, MD16, Quinlan Sievers, MD, PhD17, Raphael Steiner, MD18, Robert Stuver, MD19, Pallawi Torka, MD20, Jasmine Zain, M.D.21, Michelle Okwali, MPH22, Annie Qiu, MPH23, Andrew Zelenetz, MD24, Ariela Noy, MD25, Michael Scordo, MD26, Brandon S. Imber, MD, MA27, Gilles Salles I, MD, PhD28, Christian Grommes, MD29, Mark Roschewski, MD30, Paola Ghione31
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York, New York, United States
31 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction
De novo secondary CNS lymphoma (SCNSL), defined by synchronous CNS and systemic lymphoma at diagnosis, is a rare presentation of aggressive B-cell lymphoma with limited available prospective data. Treatment principles are guided by small phase II studies. Polatuzumab in combination with rituximab-cyclophosphamide-doxorubicin-prednisone (R-Pola-CHP) improved PFS compared to rituximab-cyclophosphamide-vincristine-doxorubicin-prednisone (R-CHOP) in the POLARIX trial (Tilly H, NEJM 2022), with preferential activity in activated B-cell type (ABC) diffuse large B-cell lymphoma (DLBCL). Given that ABC DLBCL is overrepresented in CNS lymphoma, our institution adopted R-Pola-CHP as the preferred backbone in combination with high-dose methotrexate (MR-Pola-CHP) for de novo SCNSL with concomitant CNS and systemic involvement. This study describes tolerability and outcomes of all patients treated at our institution with MR-Pola-CHP and compares the results with those of patients previously treated with high-dose methotrexate-R-CHOP (MR-CHOP).
Methods
We retrospectively analyzed patients with de novo SCNSL managed at MSK, with initial treatment from 1/2014 to 11/2025. Patients included were treated with MR-CHOP from 1/2014 to 4/2023 and with MR-Pola-CHP from 5/2023 to 11/2025. The intended treatment strategy consisted of six cycles followed by consolidative autologous stem cell transplantation or CAR T-cell therapy in eligible patients, based on treatment response, and physician discretion. All patients underwent pathology review at MSK. Response assessment was performed per Lugano criteria and CNS reassessment at mid-treatment and end of treatment, including lumbar puncture (LP) and MR brain/spine. Associations between clinical and treatment characteristics were evaluated using the chi-square test. Toxicity and treatment delays were summarized using descriptive statistics. Progression-free survival at 1 year was estimated using the Kaplan-Meier method in SAS. Median follow-up was calculated with the reverse KM method.
Results
Thirty-eight patients with de novo SCNSL treated with MR-CHOP (n=26) or MR-Pola-CHP (n=12) were included. Median age at diagnosis was 66 years (37-81 years), and 28 (74%) were male. Cell of origin was available for 37 patients: 13 (35%) had germinal center B-cell–like (GCB) and 24 (65%) had non-GCB disease; cell of origin was unknown in 1 patient. Parenchymal CNS involvement was present in 16 patients (42%), including 3 with concurrent leptomeningeal disease, while 22 patients (58%) had only leptomeningeal disease; 2 patients also had vitreoretinal disease. Baseline characteristics were similar between the MR-CHOP and MR-Pola-CHP cohorts, with no statistically significant differences observed. In total, 10/12 patients (83%) were able to complete the planned 6 cycles of MR-Pola-CHP. One patient completed five cycles, and one completed only three cycles because of AKI following HD-MTX. Three patients (25%) required MTX dose reduction. Complete response rate after MR-Pola-CHP was 75% (n=9), with 3 patients experiencing disease progression, versus 76% (n=20) after MR-CHOP (1 death, 4 progressions, 1 partial response). After MR-Pola-CHP, 4 patients (33%) proceeded to thiotepa-based high-dose chemotherapy (HD) and autologous stem cell rescue. Four patients (33%) relapsed before receiving consolidation (3 in CNS and 1 systemic); these patients received further treatment and 2 ultimately received CAR T consolidation. The remaining 4 patients were deemed unfit to proceed to consolidation, 3 due to age and one because of prostate cancer requiring treatment. These patients remain under observation. After MR-CHOP, 5 patients (19%) proceeded to HD treatment and autologous stem cell rescue. With a median follow-up of 17 months for MR-Pola-CHP, PFS and OS at one year were 73% and 100%, respectively, as opposed to 54% and 80% with MR-CHOP. The main grade 3-4 toxicity with MR-Pola-CHP was renal toxicity, with AKI post HD-MTX in 2/12 patients.
Conclusions
Treatment with MR-Pola-CHP was a feasible option in patients with de novo SCNSL and was associated with encouraging 1-year PFS and OS. The present data support further evaluation of MR-Pola-CHP as a promising treatment strategy for this hard-to-treat population.
DISCLOSURES
Philipp Berning, MD: Neovii Pharmaceuticals - Other (including travel support)